NY-MEDICREA
20.9.2018 15:09:05 CEST | Business Wire | Press release
The Medicrea Group (Euronext Growth Paris: FR0004178572 – ALMED, PEA-PME eligible, and OTCQX: MNRTY and MNRTF), pioneering the transformation of spinal surgeries through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI (Adaptive Spine Intelligence) technology, announced today that the Company is attending the Eurospine 2018 meeting taking place in Barcelona, Spain, from September 19th to 21st , where UNiD™ LAB biomedical engineers will showcase the most recent developments of the Company’s UNiD™ ASI technology.
Denys Sournac, President and Chief Executive Officer, stated, “At Eurospine 2018, our team of biomedical engineers will show attending spine surgeons how the UNiD™ASI technology answers the gap left by traditional implant manufacturers through a demonstration of the UNiD™ HUB, a software platform that fully integrates surgical planning through machine learning to generate personalized implants that are adapted to each individual patient and at the same time to each individual surgeon technique.”
Five years after its initial launch in September 2013, over 2,800 patients have benefited from UNiD™ ASI 100% proprietary pre-operative planning technologies and services associated with patient-specific spinal realignment rods, with a strong acceleration in adoption rate in 2018 (+60% cases in year-to-date 2018) especially in the USA.
Since its inception, the technology supported surgeons specializing in adult indications with planning services and patient-specific implants focused on restoring sagittal alignment. More recently, surgeons have found the technology to be fully applicable to the pediatric population as well. As such, surgeons have increasingly published on the application of UNiD™ ASI in pediatrics and have begun to demonstrate the importance of respecting sagittal parameters in the pediatric population.
Jean-Luc Clément, M.D. of Fondation Lenval (Nice, FRANCE) and UNiD™ASI user recently published the Article titled “Surgical Increase of Thoracic Kyphosis Increases Unfused Lumbar Lordosis in Selective Fusion for Thoracic Adolescent Idiopathic Scoliosis” . In this article, Jean-Luc Clément emphasizes “...the importance of restoring adequate kyphosis and respecting the links between sagittal parameters (thoracic kyphosis, lumbar lordosis and pelvic incidence) specifically in adolescent surgery. A task which is close to impossible for a surgeon without the appropriate tools that are now provided by Medicrea through UNID™ ASI Platform. Data analytics and predictive modeling are topics that surgeons and healthcare professionals recognize will shape the future of care and the way we view spine surgery.”
The recent publication by Jean-Luc Clément, M.D. et al. hypothesizes that correction of hypokyphosis in AIS increases lumbar lordosis, especially its proximal part by reciprocal changes. The study involves 111 patients selectively instrumented using the ST2R technique on the thoracic region with 2 years of follow-up. The author demonstrates and evaluates that non-instrumented lumbar lordosis was directly increased and proportionally impacted by the thoracic kyphosis correction.
Jean-Luc Clément also stated, “These results are supporting the use of the UNiD™ ASI platform to obtain the expected patient-specific thoracic kyphosis to adapt lumbar lordosis to the patient’s specific pelvic incidence.”
Medicrea’s proprietary UNiD™ ASI technology and services integrates numerous proprietary predictive models, one of which takes into consideration the post-operative compensatory mechanisms occurring on the non-instrumented portion of the spine both above and below the construct. Through the UNiD™ HUB, the algorithms use large amounts of data to generate intelligent surgical planning through machine learning while simultaneously allowing the surgeon to perform detailed, custom analysis of the cases. Medicrea uses proprietary data science to drive improved outcomes and economic efficiencies in spine surgery.
Meeting attendees are invited to learn more about Medicrea at Booth 33B.
About Medicrea (www.medicrea.com)
Through the lens of predictive medicine, Medicrea leverages its proprietary software analysis tools with big data and machine learning technologies supported by an expansive collection of clinical and scientific data. The Company is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.
Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 200 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D- printed titanium patient-specific implants.
For further information, please visit: Medicrea.com.
Connect with Medicrea
FACEBOOK
| INSTAGRAM
| TWITTER
| WEBSITE
| YOUTUBE
Medicrea
is listed on
EURONEXT Growth Paris
ISIN:
FR 0004178572
Ticker:
ALMED
LEI:
969500BR1CPTYMTJBA37
Medicrea is traded on
OTCQX Best Market
Tickers:
MNRTY & MRNTF
View source version on businesswire.com: https://www.businesswire.com/news/home/20180920005476/en/
Contact:
Medicrea Denys Sournac Founder, Chairman and CEO dsournac@medicrea.com or Fabrice Kilfiger, +33 (0)4 72 01 87 87 Chief Financial Officer fkilfiger@medicrea.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom